References
- National Institute for Health and Clinical Excellence. Appraising life-extending, end of life treatments [Internet]. NICE. 2009 Jul. Available from: https://www.nice.org.uk/guidance/gid-tag387/resources/appraising-life-extending-end-of-life-treatments-paper2
- National Institute for Health and Care Excellence. Discounting of health benefits in special circumstances [Internet]. NICE. 2011 Jul. Available from: https://www.nice.org.uk/guidance/ta235/resources/osteosarcoma-mifamurtide-discounting-of-health-benefits-in-special-circumstances2
- National Institute for Health and Care Excellence. Consultation paper - value based assessment of health technologies [Internet]. NICE. 2014. Available from: https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisals/VBA-TA-Methods-Guide-for-Consultation.pdf
- NHS England Cancer Drugs Fund Team. Appraisal and funding of cancer drugs from July 2016 (including the new Cancer Drugs Fund) - a new deal for patients, taxpayers and industry. NHS England [Internet]. 2016 Jul. Available from: https://www.england.nhs.uk/wp-content/uploads/2013/04/cdf-sop.pdf
- National Institute for Health and Care Excellence (NICE) and NHS England. Proposals for changes to the arrangements for evaluating and funding drugs and other health technologies appraised through NICE’s technology appraisal and highly specialised technologies programmes [Internet]. NICE and NHS England. 2016 Oct. Available from: https://www.nice.org.uk/Media/Default/About/what-we-do/our-programmes/technology-appraisals/NICE_NHSE_TA_and_HST_consultation_document.pdf
- National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal 2008. London: NICE; 2008.
- National Institute for Health and Care Excellence. Methods of technology appraisal consultation [Internet]. 2014 [cited 2017 May 2]. Available from: https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/methods-of-technology-appraisal-consultation
- NICE. Changes to NICE drug appraisals: what you need to know. National Institute for Health and Care Excellence [Internet]. 2017 Apr 4 [cited 2017 May 2]. Available from: https://www.nice.org.uk/news/feature/changes-to-nice-drug-appraisals-what-you-need-to-know
- Department of Health and the Association of the British Pharmaceutical Industry. The pharmaceutical price regulation scheme 2014 [Internet]. Department of Health and the Association of the British Pharmaceutical Industry; 2013 Dec. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/282523/Pharmaceutical_Price_Regulation.pdf
- Department of Health. Equity and excellence: liberating the NHS [Internet]. Department of Health. 2010 Jul. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/213823/dh_117794.pdf
- McCabe C, Paul A, Fell G, et al. Cancer drugs fund 2.0: a missed opportunity? Pharmacoeconomics. 2016;34:629–633. DOI:10.1007/s40273-016-0403-2
- Daniels N, Sabin J. The ethics of accountability in managed care reform. Health Aff. 1998;17:50–64. Available: https://www.ncbi.nlm.nih.gov/pubmed/9769571
- Schlander M. NICE accountability for reasonableness: a qualitative study of its appraisal of treatments for attention-deficit/hyperactivity disorder (ADHD). Curr Med Res Opin. 2007;23:207–222. DOI:10.1185/030079906X159461
- Daniels N. Accountability for reasonableness. BMJ. 2000;321:1300–1301. Available: https://www.ncbi.nlm.nih.gov/pubmed/11090498
- Daniels N, Sabin JE. Accountability for reasonableness: an update. BMJ. 2008;337:a1850. DOI:10.1136/bmj.a1850
- Paulden M, O’Mahony JF, Culyer AJ, et al. Some inconsistencies in NICE’s consideration of social values. Pharmacoeconomics. 2014;32:1043–1053. DOI:10.1007/s40273-014-0204-4
- National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal 2004. London: NICE; 2004.
- National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013 [Internet]. London: NICE; 2013 Apr. Available: http://www.nice.org.uk/process/pmg9
- Claxton K, Martin S, Soares M, et al. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess. 2015;19:1–503,v–vi. DOI:10.3310/hta19140
- Barnsley P, Towse A, Karlsberg Schaffer S, et al. Critique of CHE research paper 81: methods for the estimation of the NICE cost-effectiveness threshold [Internet]. Office of Health Economics. 2013. Available from: https://www.ohe.org/publications/critique-che-research-paper-81-methods-estimation-nice-cost-effectiveness-threshold
- Claxton K, Sculpher M. Response to the OHE critique of CHE Research paper 81 [Internet]. University of York. 2013. Available from: https://www.york.ac.uk/media/che/documents/Response%20to%20the%20OHE%20critique%20of%20CHE%20Research%20paper%2081.pdf
- Claxton K, Martin S, Soares M, et al. Opportunity Cost Calculator [Internet]. 2015 [cited 2017 May 02]. Available from: https://www.york.ac.uk/che/research/teehta/thresholds/
- Culyer AJ. Equity - some theory and its policy implications. J Med Ethics. 2001;27:275–283. Available: https://www.ncbi.nlm.nih.gov/pubmed/11479360
- Culyer AJ. Need: the idea won’t do—but we still need it. Soc Sci Med. 1995;40:727–730. DOI:10.1016/0277-9536(94)00307-F
- Paulden M. Opportunity cost and social values in health care resource allocation [Internet] [PhD]. McCabe C, editor. University of Alberta; 2016. DOI:10.7939/R3M902D4P
- Sendi P, Gafni A, Birch S. Opportunity costs and uncertainty in the economic evaluation of health care interventions. Health Econ. 2002;11:23–31. DOI:10.1002/hec.641